---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-008493"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:46:00.607265+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic receives $4.5M CEPI grant for C1 fungus-based vaccine development

## Summary
- CEPI awards $4.5M to non-profit FBS for proof-of-concept using Dyadic's C1 fungus to produce vaccine antigens.
- Goal: reduce vaccine production and release time to 35 days, versus 4-6 months for mammalian cell lines.
- Project will compare SARS-CoV-2 spike protein produced in C1 vs. mammalian cells for structure and immunogenicity.
- Technology aims to enable faster, scalable, and affordable vaccine manufacturing for pandemic response (100 Days Mission).
- Dyadic's CEO notes support for global health security and One Health approach.

## SEC filing metadata
- accession: 0001437749-25-008493
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774925008493/0001437749-25-008493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774925008493/dyai20250319_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-008493
- JSON: https://secwatch.observer/filing/0001437749-25-008493.json
- Plain text: https://secwatch.observer/filing/0001437749-25-008493.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.